Teclistamab,99.71%
产品编号:Bellancom-P99392| CAS NO:2119595-80-9
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Teclistamab
产品介绍 | Teclistamab 是一种人源化的 BCMA 和 CD3 双特异性抗体,可识别靶细胞上的 BCMA 和 T 细胞上的 CD3,诱导 T 细胞介导的细胞毒性,导致 T 细胞的活化和随后的靶细胞裂解。Teclistamab 可用于多发性骨髓瘤等相关疾病研究。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
生物活性 | Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM). | ||||||||
体外研究 |
Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性,在 H929 细胞中的 EC50 值为 0.15 nM,在MM.1R 细胞系中为 0.06 nM,在 RPMI 8226 细胞系中为 0.45 nM。 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||
体内研究 |
Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG(NOD/SCID/γc-/)小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
体内研究 |
Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG(NOD/SCID/γc-/)小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
性状 | Liquid | ||||||||
溶解性数据 | |||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||
参考文献 |